Hemcheck Sweden AB has signed a 4-month evaluation agreement with potential continuation into a 24-month long distribution agreement with Hettich Labinstrument ApS (”Hettich”), regarding the Danish market. Hettich is one of the leading distributors of medical equipment in Denmark.

The agreement is formed to evaluate a potential collaboration, and Hettich has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR, should the agreement be extended after the evaluation period.

– Hettich is a well renowned distributor in Denmark, with a profile that fits Hemcheck. They have been very clear that they believe a lot in our products, and we look forward to working with them and hope for a successful collaboration, says Joen Averstad, CEO of Hemcheck.

– We look forward to collaborating with Hemcheck and we will directly start the evaluation by e.g., attending one of the biggest trade fairs in Denmark and starting product tests at end customers, says Søren Riis Vestergaard, CEO of Hettich. 

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hettich Labinstrument ApS

Hettich was founded in 2001. The company is one of the leading distributors of medical and laboratory equipment in Denmark. Hettich is e.g., a local partner to the global manufacturer Greiner Bio-One and Andreas Hettich GmbH & Co. with focus on pre-analytics.

Read more at: https://www.hettich.dk/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.